Contributing to the promise of Surgical Oncology
17 March 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) are meeting with more than 1,700 colleagues from around the world today at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium in Seattle, USA. The theme of the meeting is “discovering the promise of what’s possible” and invites attendees to learn about the exciting possibilities for improving oncologic outcomes for patients.
The conference provides surgical oncology leaders with an opportunity to share research and network to advance the field. Four of MIA’s current or former fellows are presenting their research to colleagues at the conference, in addition to several more in attendance.
MIA's 2016 Poche Surgical Fellow, Dr Kim Isaacs, is sharing her research at the conference. Most guidelines recommend that melanoma patients have a complete lymph node dissection after they have had a positive sentinel lymph node identified; however, this doesn’t always happen. Dr Isaacs’s research investigated the factors that influence a melanoma patient’s choice to have a complete lymph node dissection or not. This research will help determine why some patients are not going ahead with this potentially life-saving surgery.
Research fellow, Trine Schoenfeldt, from Denmark is presenting her MIA research that is looking at the ideal surgical management for patients who have melanoma metastases in the sentinel nodes located near their armpit (specifically the triangular intermuscular space). How to manage patients with these metastases is considered controversial for surgeons, so having scientific evidence about the best course of treatment will ensure the best care for patients.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.